GEMATOPROTECTION EFFECTS OF DICARBAMINE AT COURSE HEALTH-CARE INNOVATION IN EXPERIMENTAL RADIOGENIC DAMAGE OF THE BLOOD SYSTEM

Moiseeva Inessa Yakovlevna, Doctor of medical sciences, professor, head of sub-department of general and clinical pharmacology, Medical Institute, Penza State University, moiseeva_pharm@ mail.ru
Ionicheva Lyubov Vladimirovna, Candidat of medical sciences, associate professor, sub-department of human physiology, Penza State University, dvilv@mail.ru
Nikishin Sergey Alexandrovich, Practitioner, Regional oncologic dispensary, nikishins@rambler.ru
Zinovyev Alexander Ivanovich, Practicioner, radiological department,Regional oncologic dispensary, alivzi@yandex.ru
Nebolsin Vladimir Evgenyevich, CEO, “Farminterprises” Ltd., nve1970@mail.ru

615.273.3+614.84

The authors have studied the influence of dicarbamin in dose 4 mg/kg by medical-prophylactic oral injection during 15 days on a leukocytic formula of peripheral rabbit blood in conditions of the experimental bone-marrow syndrome. The observable drug statistically significantly decreases intensity of postirradiation thrombocytopenia, depth and duration of leukocytopenia at the expense of seg-mented neutrophils and lymphocytes.

dicarbamin, irradiation, leukocytic formula of peripheral blood.